{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:11:14Z","timestamp":1791569474797,"version":"4.3.4"},"reference-count":48,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2011,1,4]],"date-time":"2011-01-04T00:00:00Z","timestamp":1294099200000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic hepatitis B virus (HBV) infections remain a major public health problem worldwide. According to World Health Organization estimates, more than 300 million people are chronically infected and exposed to the risk of developing severe complications including cirrhosis and hepatocellular carcinoma (HCC). Major progress in the treatment of chronic hepatitis B (CHB) has been made during the last decade with the development of antivirals that inhibit viral polymerase activity. Antiviral drug resistance is an important factor in determining the success of long\u2010term therapy for CHB. The development of resistance to nucleoside analogues (NUCs) has been associated with exacerbations of liver disease. Sequential therapy increases the risk of the emergence of multidrug resistance. The selection of a potent antiviral with a high barrier to resistance as a first\u2010line therapy provides the best chance of achieving long\u2010term treatment goals and should be used whenever possible. This has led to a significant decrease in drug resistance in countries where this strategy is affordable. However, the barrier to resistance of a given antiviral agent is influenced by the genetic barrier, drug potency, patient adherence, pharmacological barrier, viral fitness, the drug mechanisms of action and cross resistance. Furthermore, because of specific viral kinetics, prolonged treatment with NUCs does not result in the clearance of the viral genome from the infected liver. It is therefore important to continue research to identify new viral and immune targets and develop novel antiviral strategies for controlling viral replication as well as preventing drug resistance and its complications in the long term.<\/jats:p>","DOI":"10.1111\/j.1478-3231.2010.02399.x","type":"journal-article","created":{"date-parts":[[2011,1,4]],"date-time":"2011-01-04T15:16:48Z","timestamp":1294154208000},"page":"111-116","source":"Crossref","is-referenced-by-count":123,"title":["Hepatitis B virus resistance to antiviral drugs: where are we going?"],"prefix":"10.1111","volume":"31","author":[{"given":"Fabien","family":"Zoulim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,1,4]]},"reference":[{"issue":"1","key":"e_1_2_19_2_2","first-page":"S2","article-title":"Hepatitis B","volume":"48","author":"Zoulim F","year":"2008","journal-title":"reflections on the current approach to antiviral therapy"},{"key":"e_1_2_19_3_2","first-page":"227","article-title":"EASL Clinical Practice Guidelines","volume":"50","author":"European Association for the study of the Liver.","year":"2009","journal-title":"management of chronic hepatitis B"},{"key":"e_1_2_19_4_2","first-page":"661","article-title":"Chronic hepatitis B","volume":"50","author":"Lok AS","year":"2009","journal-title":"update 2009"},{"key":"e_1_2_19_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.1.65"},{"key":"e_1_2_19_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033364"},{"key":"e_1_2_19_7_2","article-title":"Long\u2010term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B","author":"Chang TT","journal-title":"Hepatology"},{"key":"e_1_2_19_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802878"},{"key":"e_1_2_19_9_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.09.020"},{"key":"e_1_2_19_10_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.50013"},{"key":"e_1_2_19_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040431"},{"key":"e_1_2_19_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043470"},{"key":"e_1_2_19_13_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.08.063"},{"key":"e_1_2_19_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/368083"},{"key":"e_1_2_19_15_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.09.033"},{"key":"e_1_2_19_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22414"},{"key":"e_1_2_19_17_2","first-page":"486","article-title":"2\u2010Year GLOBE Trial Results","volume":"136","author":"Liaw YF","year":"2009","journal-title":"Telbivudine is superior to Lamivudine in patients with chronic hepatitis B"},{"key":"e_1_2_19_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23327"},{"key":"e_1_2_19_19_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.19619"},{"key":"e_1_2_19_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840400418"},{"key":"e_1_2_19_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21290"},{"key":"e_1_2_19_22_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.08.013"},{"key":"e_1_2_19_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.11.016"},{"key":"e_1_2_19_24_2","first-page":"493","article-title":"Antiviral effect of entecavir in chronic hepatitis B","volume":"52","author":"Reijnders JG","year":"2010","journal-title":"influence of prior exposure to nucleos(t)ide analogues"},{"key":"e_1_2_19_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23246"},{"key":"e_1_2_19_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.01.027"},{"key":"e_1_2_19_27_2","first-page":"263","article-title":"Asian\u2010Pacific consensus statement on the management of chronic hepatitis B","volume":"2","author":"Liaw YF","year":"2008","journal-title":"a 2008 update"},{"key":"e_1_2_19_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(89)90455-8"},{"key":"e_1_2_19_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02011-08"},{"key":"e_1_2_19_30_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.27563"},{"key":"e_1_2_19_31_2","first-page":"936","article-title":"A treatment algorithm for the management of chronic hepatitis B virus infection in the United States","volume":"4","author":"Keeffe EB","year":"2006","journal-title":"an update"},{"key":"e_1_2_19_32_2","first-page":"890","article-title":"Report of an international workshop","volume":"5","author":"Keeffe EB","year":"2007","journal-title":"Roadmap for management of patients receiving oral therapy for chronic hepatitis B"},{"key":"e_1_2_19_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21939"},{"key":"e_1_2_19_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22841"},{"key":"e_1_2_19_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.3.1613-1622.2005"},{"key":"e_1_2_19_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1389"},{"key":"e_1_2_19_37_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.01.001"},{"key":"e_1_2_19_38_2","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1128\/AAC.42.12.3179","article-title":"Inhibition of human hepatitis B virus replication by AT\u201061, a phenylpropenamide derivative, alone and in combination with (\u2010)b\u2010L\u20102\u2032,3\u2032\u2010dideoxy\u20103\u2032\u2010thiacytidine","volume":"42","author":"King RW","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_19_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.9.3057-3060.2002"},{"key":"e_1_2_19_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(01)00216-9"},{"key":"e_1_2_19_41_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1077215"},{"key":"e_1_2_19_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2007.04.004"},{"key":"e_1_2_19_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0598-610"},{"key":"e_1_2_19_44_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1294"},{"key":"e_1_2_19_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23230"},{"key":"e_1_2_19_46_2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/135965350901400115","article-title":"Inhibitory effect of the combination of CpG\u2010induced cytokines with lamivudine against hepatitis B virus replication in vitro","volume":"14","author":"Vincent IE","year":"2009","journal-title":"Antivir Ther"},{"key":"e_1_2_19_47_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20072076"},{"key":"e_1_2_19_48_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI33402"},{"key":"e_1_2_19_49_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20061287"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2010.02399.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2010.02399.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T07:53:13Z","timestamp":1694591593000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2010.02399.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":48,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["10.1111\/j.1478-3231.2010.02399.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2010.02399.x","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}